27 August 2003
A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancyDeborah L. Toppmeyer, Murugesan Gounder, Judie Much, Rita Musanti, Viral Vyas, Melissa Medina, Tammy Orlando, Michael Pennick, Yong Lin, Weichung Shih, Susan Goodin, Eric H. Rubin
Med Sci Monit 2003; 9(8): PI99-104 :: ID: 13110
BACKGROUND: Marimastat is a potent inhibitor of matrix metalloproteinases and in preclinical studies enhances the anti-tumor activity of certain chemotherapeutics. We performed a phase I clinical evaluation of the combination of oral marimastat and intravenous paclitaxel, to determine if these drugs could be co-administered safely, and to determine whether marimastat alters paclitaxel pharmacokinetics.Material/Methods:Marimastat was administered twice daily and paclitaxel as a three hour infusion every three weeks. Doses of both marimastat and paclitaxel were escalated in cohorts of patients up to maximal doses of 10 mg for marimastat and 175 mg/m2 for paclitaxel. Paclitaxel plasma pharmacokinetic parameters were assessed in the absence (cycle 1) and presence (cycle 2) of marimastat. Trough marimastat plasma levels were evaluated during cycle 2.Results:A total of 19 patients were treated at three different dose levels. There were no dose-limiting toxicities during the first cycle of therapy, resulting in dose escalation up to the planned maximal dose for each drug. Neutropenia was the most common significant toxicity at the highest dose level, with grade 3 or higher neutropenia occurring in 38% of patients. There were no complete or partial responses. Pharmacokinetic analyses indicate that marimastat does not alter paclitaxel clearance. At the 10 mg dose, the mean trough marimastat level was 14.8 Kg/L.Conclusions:Marimastat and paclitaxel can be co-administered safely at doses equivalent to those recommended for single-agent administration. Additional studies are necessary to determine whether this combination is more effective in controlling tumor progression than paclitaxel alone.
Keywords: Adult, Antineoplastic Agents, Phytogenic - chemistry, Antineoplastic Agents, Phytogenic - pharmacokinetics, Antineoplastic Agents, Phytogenic - therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Enzyme Inhibitors - chemistry, Enzyme Inhibitors - pharmacokinetics, Enzyme Inhibitors - therapeutic use, Hydroxamic Acids - chemistry, Hydroxamic Acids - pharmacokinetics, Hydroxamic Acids - therapeutic use, Molecular Structure, Neoplasms - drug therapy, Paclitaxel - chemistry, Paclitaxel - pharmacokinetics, Paclitaxel - therapeutic use
This Week Editorial
02 August 2021 : EditorialEditorial: The National COVID Cohort Collaborative Consortium Combines Population Data with Machine Learning to Evaluate and Predict Risk Factors for the Severity of COVID-19
Med Sci Monit 2021; 27:e934171
30 July 2021 : Clinical ResearchRural and Female Patients with Old Myocardial Infarction Lacked Knowledge and Preventive Measures During th...
Med Sci Monit In Press :: DOI: 10.12659/MSM.928512
16 July 2021 : Review articleSilent Hypoxemia in Patients with COVID-19 Pneumonia: A Review
Med Sci Monit In Press :: DOI: 10.12659/MSM.930776
09 July 2021 : Database AnalysisA Simple Clinical Prediction Tool for COVID-19 in Primary Care with Epidemiology: Temperature-Leukocytes-CT...
Med Sci Monit In Press :: DOI: 10.12659/MSM.931467
03 Aug 2021 : Clinical ResearchComparison of Outcomes Following TiRobot-Assisted Sacroiliac Screw Fixation with Bone Grafting and Traditio...
Med Sci Monit In Press :: DOI: 10.12659/MSM.932724
02 Aug 2021 : Database AnalysisRNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape...
Med Sci Monit In Press :: DOI: 10.12659/MSM.930994
02 Aug 2021 : Clinical ResearchVitamin D Receptor Is a Sepsis-Susceptibility Gene in Chinese Children
Med Sci Monit In Press :: DOI: 10.12659/MSM.932518
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700